Literature DB >> 23652586

Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.

Ahmed M L Bedewy1, Maha M Adel Elgammal, Magdy M L Bedewy, Shereen M El-Maghraby.   

Abstract

UNLABELLED: The soluble decoy receptor 3 (DcR3) is a member of the tumor necrosis factor receptor superfamily whose overexpression has been observed in several human malignancies. Survivin is one of the inhibitors of apoptosis proteins that are thought to play an important role in the pathogenesis of malignancies. We aimed to evaluate the expression of DcR3 in relation to survivin in B cell non-Hodgkin`s lymphoma (NHL) and then we focused on patients with diffuse large B cell non-Hodgkin's lymphoma (DLBCL) (50 cases) and correlated DcR3 expression with survivin expression and other prognostic parameters. Fifteen subjects with reactive lymphoid hyperplasia were included as controls. The expression of DcR3 and survivin were analyzed by immunohistochemistry on formalin-fixed paraffin-embedded lymph node sections from 80 cases of B cell NHL and 15 controls. Bone marrow biopsy sections of patients were also immunostained with the previous markers.
RESULTS: DcR3 expression was found in 32.5% of B cell NHL patients versus 6.7% of controls (p <0.001) and was associated with the aggressive/highly aggressive subtypes. DcR3 was strongly expressed in 30% of DLBCL patients, where it was associated with survivin expression, high international prognostic index (IPI), the presence of extra nodal disease, ECOG performance status >1, reduced remission rates and shorter event-free survival. The expression of survivin was 40% in B cell NHL patients versus 13.3% in the control group (p <0.001). The expression of survivin in aggressive/highly aggressive B cell NHL was significantly higher than that in indolent B cell NHL. Survivin expression has been detected in 44% of the DLBCL patients and was associated with their clinical stage and shorter event-free survival (p = 0.026). Bone marrow biopsy sections from DLBCL patients showed significant DcR3 and survivin over expressions in sections with infiltration by lymphoma cells than sections with no infiltration.
CONCLUSION: DcR3 expression was associated with other prognostic factors including survivin, reduced remission rates, and shorter event-free survival. Survivin is closely related to aggressive/highly aggressive subtypes of B cell NHL and is associated with shorter event-free survival. Both DcR3 and survivin expressions on bone marrow sections can be of help in diagnosing bone marrow infiltration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23652586     DOI: 10.1007/s00277-013-1775-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.

Authors:  Wen Zeng; Fankai Meng; Zeming Liu; Xia Mao; Li Luo; Miao Zheng; Shuang Qin; Wenli Liu; Jianfeng Zhou; Hanying Sun; Lifang Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Prognostic value of survivin in patients with non-Hodgkin's lymphoma: a meta-analysis.

Authors:  Chuan He; Zhigang Liu; Jie Ji; Huanling Zhu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

4.  Protocadherin γ A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth.

Authors:  Xueyan Zhang; Katsuyoshi Takata; Wei Cui; Tomoko Miyata-Takata; Yasuharu Sato; Mai Noujima-Harada; Tadashi Yoshino
Journal:  Mol Med Rep       Date:  2016-10-05       Impact factor: 2.952

5.  Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Authors:  Jung Yong Hong; Kyung Ju Ryu; Chaehwa Park; Mineui Hong; Young Hyeh Ko; Won Seog Kim; Seok Jin Kim
Journal:  Oncotarget       Date:  2017-02-21

6.  Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma: A Meta-Analysis.

Authors:  Ya Zhang; Jianhong Wang; Xiaohui Sui; Ying Li; Kang Lu; Xiaosheng Fang; Yujie Jiang; Xin Wang
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

7.  Intravascular large B-cell lymphoma associated with myelofibrosis: A case report.

Authors:  Jong Gwon Choi; Hwan Hwi Cho; Sang Rok Kang; Se Min Jang; Eun Hyung Yoo; Hyun Jung Cho; Sun Moon Kim; Do Yeun Cho
Journal:  Mol Clin Oncol       Date:  2017-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.